Metagenomi Therapeutics Inc (MGX): Next-Year EPS Estimate 26.30%
As of 2026-06-11, Metagenomi Therapeutics Inc (MGX) has a next-year EPS growth estimate of 26.30%.
On 2026-05-14, analyst consensus for MGX's next-year EPS growth shifted from 25.30% to 26.30% — a positive change of 1.00 percentage points. The revised estimate has been sustained across 21 subsequent trading sessions. Current-year growth is projected at 10.01%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 26.30%
- EPS growth this year
- 10.01%
- EPS next quarter (est)
- -$0.58
- Last price
- $1.25
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 26.30% | 10.01% | -$0.58 | $1.25 |
| 2026-06-10 | 26.30% | 10.01% | -$0.58 | $1.23 |
| 2026-06-09 | 26.30% | 10.01% | -$0.58 | $1.23 |
| 2026-06-08 | 26.30% | 10.01% | -$0.58 | $1.29 |
| 2026-06-07 | 26.30% | 10.01% | -$0.58 | $1.28 |
| 2026-06-04 | 26.30% | 10.01% | -$0.58 | $1.33 |
| 2026-06-03 | 26.30% | 10.01% | -$0.58 | $1.33 |
| 2026-06-02 | 26.30% | 10.01% | -$0.58 | $1.33 |
| 2026-06-01 | 26.30% | 10.01% | -$0.58 | $1.31 |
| 2026-05-31 | 26.30% | 10.01% | -$0.58 | $1.36 |
| 2026-05-28 | 26.30% | 10.01% | -$0.58 | $1.40 |
| 2026-05-27 | 26.30% | 10.01% | -$0.58 | $1.35 |
| 2026-05-26 | 26.30% | 10.01% | -$0.58 | $1.36 |
| 2026-05-25 | 26.30% | 10.01% | -$0.58 | $1.35 |
| 2026-05-24 | 26.30% | 10.01% | -$0.58 | $1.35 |
| 2026-05-21 | 26.30% | 10.01% | -$0.58 | $1.31 |
| 2026-05-20 | 26.30% | 10.01% | -$0.58 | $1.29 |
| 2026-05-19 | 26.30% | 10.01% | -$0.58 | $1.25 |
| 2026-05-18 | 26.30% | 10.01% | -$0.58 | $1.27 |
| 2026-05-17 | 26.30% | 10.01% | -$0.58 | $1.31 |
| 2026-05-14 | 26.30% | 10.01% | -$0.58 | $1.35 |
| 2026-05-13 | 25.30% | 9.80% | -$0.58 | $1.37 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Metagenomi Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Metagenomi Therapeutics Inc (MGX) has a next-year EPS growth estimate of 26.30%, based on analyst consensus.
When was the latest EPS estimate revision for MGX?▾
The most recent revision occurred on 2026-05-14, when analysts adjusted the next-year EPS growth estimate from 25.30% to 26.30%.
What sector and industry does Metagenomi Therapeutics Inc belong to?▾
Metagenomi Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MGX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Metagenomi Therapeutics Inc (MGX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports